Suven Life Sciences Gets Product Patent in Australia, Singapore – CORPORATE ETHOS

Suven Life Sciences Gets Product Patent in Australia, Singapore

By: | January 16, 2019

Suven Life Sciences Ltd (Suven) has received product patent from Australia (2016217461) and Singapore (11201710044U) corresponding to the New Chemical Entities for the
treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036.

The granted claims of the patents include the class of selective 5-HT4 and M1 PAM compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia etc.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.